PRAS40 suppresses atherogenesis through inhibition of mTORC1-dependent pro-inflammatory signaling in endothelial cells

The pro-atherogenic response to disturbed blood flow is increased by a western diet, but not by old age

(2019) Ashley E. Walker et al.   Scientific Reports

Piezo1 and Gq/G11 promote endothelial inflammation depending on flow pattern and integrin activation

(2018) Julián Albarrán-Juárez et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Lipid sensing by mTOR complexes viade novosynthesis of phosphatidic acid

(2017) Deepak Menon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Noncanonical Pathway for Regulation of CCL2 Expression by an mTORC1-FOXK1 Axis Promotes Recruitment of Tumor-Associated Macrophages

(2017) Hirokazu Nakatsumi et al.   Cell Reports

Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis

(2016) Michael A. Gimbrone et al.   CIRCULATION RESEARCH

Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

(2016) Haidong Wang et al.   LANCET

Potential therapeutic effects of mTOR inhibition in atherosclerosis

(2015) Ammar Kurdi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

mTOR inhibition: A promising strategy for stabilization of atherosclerotic plaques

(2014) Wim Martinet et al.   ATHEROSCLEROSIS

Longevity, aging and rapamycin

(2014) Dan Ehninger et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Disruption of Mammalian Target of Rapamycin Complex 1 in Macrophages Decreases Chemokine Gene Expression and Atherosclerosis

(2014) Ding Ai et al.   CIRCULATION RESEARCH

Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2

(2014) Chen Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Rapamycin Attenuates Endothelial Apoptosis Induced by Low Shear Stress via mTOR and Sestrin1 Related Redox Regulation

(2014) Junxia Zhang et al.   MEDIATORS OF INFLAMMATION

Inhibition of the mTOR pathway: A possible protective role in coronary artery disease

(2013) Giovanni Tarantino et al.   ANNALS OF MEDICINE

A Central Role for mTOR in Lipid Homeostasis

(2013) Dudley W. Lamming et al.   Cell Metabolism

PRAS40 prevents development of diabetic cardiomyopathy and improves hepatic insulin sensitivity in obesity

(2013) Mirko Völkers et al.   EMBO Molecular Medicine

Rapamycin extends murine lifespan but has limited effects on aging

(2013) Frauke Neff et al.   JOURNAL OF CLINICAL INVESTIGATION

Rapalogs and mTOR inhibitors as anti-aging therapeutics

(2013) Dudley W. Lamming et al.   JOURNAL OF CLINICAL INVESTIGATION

Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1

(2013) M. Volkers et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of PRAS40 in Akt and mTOR signaling in health and disease

(2012) Claudia Wiza et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice

(2012) Frank Beutner et al.   ATHEROSCLEROSIS

Adverse events associated with mTOR inhibitors

(2012) Nicolas Pallet et al.   Expert Opinion On Drug Safety

Procontractile G protein–mediated signaling pathways antagonistically regulate smooth muscle differentiation in vascular remodeling

(2012) Till F. Althoff et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Sirolimus and Cardiovascular Disease Risk in Liver Transplantation

(2012) Greg J. McKenna et al.   TRANSPLANTATION

Cardiovascular Risk in Kidney Transplant Recipients Receiving Mammalian Target of Rapamycin Inhibitors

(2011) E. Watorek et al.   TRANSPLANTATION PROCEEDINGS

Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-κB dependent AP-1-mediated ICAM-1 expression in breast cancer cells

(2010) Mansoor Ahmed et al.   Molecular Cancer

Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis

(2010) Yingdi Wang et al.   NATURE

Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels

(2009) Wen Qiang Chen et al.   BRITISH JOURNAL OF PHARMACOLOGY

Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor

(2009) L Zhao et al.   BRITISH JOURNAL OF PHARMACOLOGY

Everolimus Inhibits Monocyte/Macrophage Migration in Vitro and Their Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits

(2008) R. Baetta et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS